- Home
- YALA vs IVA Comparison
YALA vs IVA Comparison
Compare YALA & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YALA | IVA |
|---|---|---|
| Founded | 2016 | 2011 |
| Country | United Arab Emirates | France |
| Employees | N/A | 77 |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 801.7M | 883.8M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | YALA | IVA |
|---|---|---|
| Price | $5.18 | $4.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $16.20 |
| AVG Volume (30 Days) | 270.1K | ★ 1.4M |
| Earning Date | 05-18-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.40 | N/A |
| Revenue Next Year | $7.13 | $751.20 |
| P/E Ratio | $8.76 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.01 | $2.94 |
| 52 Week High | $9.29 | $7.98 |
Technical Indicators
Market Signals| Indicator | YALA | IVA |
|---|---|---|
| Relative Strength Index (RSI) | 36.93 | 54.91 |
| Support Level | $5.01 | $3.96 |
| Resistance Level | $7.34 | $4.69 |
| Average True Range (ATR) | 0.13 | 0.31 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 3.53 | 70.41 |
Price Performance
Historical ComparisonAbout YALA Yalla Group Limited each representing one
Yalla Group Ltd is a MENA-based online social networking and gaming company. It operates two flagship mobile applications, Yalla, a voice-centric group chat platform, and Yalla Ludo, a casual gaming application featuring online versions of board games popular in MENA, with in-game voice chat and localized majlis functions. The group has one operating segment, which is the social networking and entertainment platform.
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.